Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-05-27

The balance of ubiquitin conjugation and deconjugation

Objectif

Ubiquitin conjugation is one of the most important signaling systems in the eukaryotic cell. Different types of mono- and polyubiquitin chains determine the fate of target proteins by redirecting them for degradation, relocalization or interaction with new partners. The type of ubiquitin modification on any target is determined by the interplay between the conjugating E2/E3 complexes on the one hand and deubiquitinating enzymes on the other. In practice, it is the balance between conjugating and deconjugating systems that determines the result of the various ubiquitination signals. For three different regulatory systems that are critical for correct genome maintenance, we are now in a position to study not just the individual process of conjugation or deconjugation in isolation, but rather, reconstitute the entire reaction on a defined physiological target. These three target systems, histone H2A, PCNA and P53, can be mono-ubiquitinated by a defined E3-ligase, poly-ubiquitinated by a second ligase and deconjugated by defined deubiquitinating enzymes in a reaction that is affected by known allosteric modulators. Our unique collection of tools to study these systems in vitro allows reconstitution of the full reaction, to trap intermediates, and to study their interaction from atomic detail to kinetic reactivity. Using X-ray crystallography of critical intermediates and kinetic analysis of individual reactions by FRET and surface plasmon resonance, we can address how the mono-, poly and deubiquitinating reactions affect each other. By answering mechanistic questions on the relative effect of the forward and backward reaction components and their modulators we will provide a solid basis for drug design studies that target these pathways against cancer development.

Appel à propositions

ERC-2009-AdG
Voir d’autres projets de cet appel

Régime de financement

ERC-AG - ERC Advanced Grant

Institution d’accueil

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Contribution de l’UE
€ 2 299 720,00
Adresse
PLESMANLAAN 121
1066 CX Amsterdam
Pays-Bas

Voir sur la carte

Région
West-Nederland Noord-Holland Groot-Amsterdam
Type d’activité
Research Organisations
Contact administratif
Henri Van Luenen (Dr.)
Chercheur principal
Titia Karen Sixma (Prof.)
Liens
Coût total
Aucune donnée

Bénéficiaires (1)